0.5015

7.30% -0.0395

Skye Bioscience Inc (SKYE)

Overview News Price History Discussions Forecast

Skye Bioscience Inc stock is traded at $0.5015, with a volume of 1.26M. It is down -7.30% in the last 24 hours and down -19.13% over the past month. Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Previous Close:

$0.541

Open:

$0.86

24h Volume:

1.26M

Relative Volume:

7.49

Market Cap:

$17.62M

Revenue:

Net Income/Loss:

$-57.33M

P/E Ratio:

-0.347

EPS:

-1.4452

Net Cash Flow:

$-42.44M

1W Performance:

-3.45%

1M Performance:

-19.13%

6M Performance:

-30.71%

1Y Performance:

-84.66%

1-Day Range:

$0.4732

$0.88

1-Week Range:

$0.4732

$0.88

52-Week Range:

$0.276

$4.9902

Skye Bioscience Inc Stock (SKYE) Company Profile

Name

Skye Bioscience Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(858) 410-0266

Address

11250 EL CAMINO REAL, SUITE 100, SAN DIEGO

Employee

Twitter

Next Earnings Date

2026-08-20

Latest SEC Filings

SKYE's Discussions on Twitter

Compare SKYE vs MOBBW, PSNYW, GOODO, SHMD, DWLD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SKYE Skye Bioscience Inc.	3.10	12.89M	0	0	0	0.00
MOBBW Mobilicom Limited Warrants	1.86	2.83B	0	0	0	0.00
PSNYW Polestar Automotive Holding Uk	2.89	388.34M	2.07B	-1.42B	-1.37B	-0.6765
GOODO Gladstone Commercial Corporation	20.88	372.90M	0	0	0	0.00
SHMD Schmid Group N V	5.45	348.74M	52.15M	-21.46M	0	-0.4675
DWLD Davis Select Worldwide ETF	48.03	0	0	0	0	0.00

Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-06-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-06-25	Downgrade	Craig Hallum	Buy → Hold
Aug-15-25	Initiated	Evercore ISI	Outperform
Feb-28-25	Initiated	William Blair	Outperform
Sep-30-24	Initiated	Scotiabank	Sector Outperform
Sep-10-24	Initiated	JMP Securities	Mkt Outperform
Jul-09-24	Initiated	Craig Hallum	Buy
May-23-24	Initiated	Cantor Fitzgerald	Overweight
Apr-12-24	Initiated	Oppenheimer	Outperform

View All

Skye Bioscience Inc Stock (SKYE) Latest News

Aug 14, 2026

Skye drops obesity program, combines with Redx to form Fibrx - AllSci

Aug 14, 2026

Skye Bioscience Q2 Loss Narrows Sharply on Lower R&D Spending - Minichart

Aug 14, 2026

SKYE: Merger creates Fibrx, a well-funded fibrosis company advancing RXC008 for Crohn's disease - TradingView

Aug 14, 2026

Skye Bioscience to Be Acquired by Redx Pharma in $264.5M Nasdaq-Listed Merger - Minichart

Aug 14, 2026

SKYE: Merger creates a well-funded fibrosis company advancing RXC008 for Crohn's disease, with phase II data due 2029 - TradingView

Aug 14, 2026

Form 8K Skye Bioscience Inc For: 14 August By Investing.com - Investing.com India

Aug 14, 2026

Skye Bioscience to acquire Redx Pharma in $125M deal By Investing.com - Investing.com UK

Aug 14, 2026

Skye Bioscience to Acquire Redx; Secures $67.9M Financing and $22M Equity Line - TradingView

Aug 14, 2026

Skye Bioscience, Inc. 2026: Revenue $178.2K, EPS ($0.27) — 10-Q Summary - TradingView

Aug 14, 2026

Skye Bioscience (NASDAQ: SKYE) exits obesity trial, pursues Redx merger and $100M+ funding - Stock Titan

Aug 14, 2026

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings - marketscreener.com

Aug 14, 2026

Aug 07, 2026